Antidepressant Medication Use in Pregnancy

Journal of Midwifery and Women's Health

Volumn 55, Issue 2, 2010, Pages 90-100

  Hackley, Barbara ^a  

^a NONE

Author keywords

antidepressant medication; depression; pregnancy; SSRI

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; VENLAFAXINE;

AMYGDALOID NUCLEUS; ANENCEPHALUS; ARTICLE; CARDIOVASCULAR MALFORMATION; CONGENITAL HEART DISEASE; CONGENITAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; DEPRESSION; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; HEALTH CARE PERSONNEL; HEART SEPTUM DEFECT; HEREDITY; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LACTATION; LOW BIRTH WEIGHT; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; OMPHALOCELE; PARKINSON DISEASE; PERSISTENT PULMONARY HYPERTENSION; PREFRONTAL CORTEX; PREGNANCY; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; PUERPERIUM; RISK FACTOR; SPONTANEOUS ABORTION; THALAMUS; THIRD TRIMESTER PREGNANCY; WOMEN'S HEALTH;

ADAPTATION, PSYCHOLOGICAL; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANT WOMEN; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS; TIME FACTORS;

EID: 77249127022     PISSN: 15269523     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmwh.2009.11.003     Document Type: Article

References (70)

1. Riolo S., Nguyen T., Greden J., and King C. Prevalence of depression by race/ethnicity: Findings from the National Health and Nutrition Examination Survey III. Am J Public Health 95 (2005) 998-1000
2. Dietz P.M., Williams S.B., Callaghan W.M., Bachman D.J., Whitlock E.P., and Hornbrook M.C. Clinically identified maternal depression before, during, and after pregnancies ending in live births. Am J Psychiatry 164 (2007) 1515-1520
3. Centers for Disease Control and Prevention. Prevalence of self-reported postpartum depressive symptoms-17 states, 2004-2005. MMWR Morb Mortal Wkly Rep 57 (2008) 361-366
4. Ferrara A. Increasing prevalence of gestational diabetes mellitus: A public health perspective. Diabetes Care 30 suppl 2 (2007) S141-S146
5. Deis S., Rouzier R., Kayem G., Masson C., and Haddad B. Development of a nomogram to predict occurrence of preeclampsia. Eur J Obstet Gynecol Reprod Biol 137 (2008) 146-151
6. LaRocco-Cockburn A., Melville J., Bell M., and Katon W. Depression screening attitudes and practices among obstetrician-gynecologists. Obstet Gynecol 101 5 part 1 (2003) 892-898
7. Williams M., and Wooltorton E. Paroxetine (Paxil) and congenital malformations. CMAJ 173 (2005) 1320-1321
8. Bonari L., Koren G., Einarson T.R., Jasper J.D., Taddio A., and Einarson A. Use of antidepressants by pregnant women: Evaluation of preception of risk, efficacy of evidence based counseling, and determinants of decision making. Arch Womens Ment Health 8 (2005) 214-220
9. Moses-Kolko E.L., Bogen D., Perel J., Bregar A., Uhl K., Levin B., et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. JAMA 293 (2005) 2372-2383
10. Hackley B. Managing mental health conditions in primary care settings. J Midwifery Womens Health 55 (2010) 9-19
11. Sullivan P.F., Neale M.C., and Kendler K.S. Genetic epidemiology of major depression: Review and meta-analysis. Am J Psychiatry 157 (2000) 1552-1562
12. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.G., and Monteggia L.M. Neurobiology of depression. Neuron 34 (2002) 13-25
13. Feder A., Nestler E.J., and Charney D.S. Psychobiology and molecular genetics of resilience. Nat Rev Neurosci 10 (2009) 446-457
14. Joska J.A., and Stein D.J. Mood disorders. In: Hales R.E., Yudofsky S.C., and Gabbard G.O. (Eds). Textbook of psychiatry. 5th ed (2008), American Psychiatric Publishing, Arlington, VA
15. Ressler K.J., and Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12 suppl 1 (2000) 2-19
16. aan het Rot M., Mathew S.J., and Charney D.S. Neurobiological mechanisms in major depressive disorder. CMAJ 180 (2009) 305-313
17. Neale D.M., Cootauco A.C., and Burrow G. Thyroid disease in pregnancy. Clin Perinatol 34 (2007) 543-557
18. Sherwin B. Estrogen and mood in women. Endocrinologist 15 (2005) 180-185
19. Steiner M., Dunn E., and Born L. Hormones and mood: From menarche to menopause and beyond. J Affect Disord 74 (2003) 67-83
20. Klier C.M., Muzik M., Dervic K., Mossaheb N., Benesch T., Ulm B., et al. The role of estrogen and progesterone in depression after birth. J Psychiatr Res 41 (2007) 273-279
21. Jacobs N., Kenis G., Peeters F., Derom C., Vlietinck R., and van Os J. Stress-related negative affectivity and genetically altered serotonin transporter function: Evidence of synergism in shaping risk of depression. Arch Gen Psychiatry 63 (2006) 989-996
22. Scheid J.M., Holzman C.B., Jones N., Friderici K.H., Nummy K.A., Symonds L.L., et al. Depressive symptoms in mid-pregnancy, lifetime stressors and the 5-HTTLPR genotype. Genes Brain Behav 6 (2007) 453-464
23. Tomb D. Biologic therapy. In: Tomb D. (Ed). Psychiatry (2008), Lippincott Williams & Wilkins, Philadelphia, PA
24. Nock M.K., Borges G., Bromet E.J., Cha C.B., Kessler R.C., and Lee S. Suicide and suicidal behavior. Epidemiol Rev 30 (2008) 133-154
25. Bonari L., Pinto N., Ahn E., Einarson A., Steiner M., and Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 40 (2004) 726-735
26. Gavin A.R., Chae D.H., Mustillo S., and Kiefe C.I. Prepregnancy depressive mood and preterm birth in black and white women: Findings from the CARDIA study. J Womens Health (Larchmt) 18 (2009) 803-811
27. Entringer S., Kumsta R., Hellhammer D.H., Wadhwa P.D., and Wüst S. Prenatal exposure to maternal psychosocial stress and HPA axis regulation in young adults. Horm Behav 55 (2009) 292-298
28. Beydoun H., and Saftlas A.F. Physical and mental health outcomes of prenatal maternal stress in human and animal studies: A review of recent evidence. Paediatr Perinat Epidemiol 22 (2008) 438-466
29. Bergman K., Sarkar P., O'Connor T.G., Modi N., and Glover V. Maternal stress during pregnancy predicts cognitive ability and fearfulness in infancy. J Am Acad Child Adolesc Psychiatry 46 (2007) 1454-1463
30. Davis E.P., Glynn L.M., Schetter C.D., Hobel C., Chicz-Demet A., and Sandman C.A. Prenatal exposure to maternal depression and cortisol influences infant temperament. J Am Acad Child Adolesc Psychiatry 46 (2007) 737-746
31. Hobel C.J., Goldstein A., and Barrett E.S. Psychosocial stress and pregnancy outcome. Clin Obstet Gynecol 51 (2008) 333-348
32. Yonkers K.A., Wisner K.L., Stewart D.E., Oberlander T.F., Dell D.L., Stotland N., et al. The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. General Hospital Psychiatry 31 (2009) 403-413
33. Suri R., Altshuler L., Hellemann G., Burt V.K., Aquino A., and Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 164 (2007) 1206-1213
34. Wisner K.L., Sit D.K.Y., Hanusa B.H., Moses-Kolko E.L., Bogen D.L., Hunker D.F., et al. Major depression and antidepressant treatment: Impact on pregnancy and neonatal outcomes. Am J Psychiatry 166 (2009) 557-566
35. Lund N., Pedersen L.H., and Henriksen T.B. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 163 (2009) 949-954
36. ACOG Practice Bulletin. Use of psychiatric medications during pregnancy and lactation: Clinicial management guidelines for obstetrician-gynecologists, number 92. Obstet Gynecol 111 (2008) 1001-1020
37. Gonsalves L., and Schuermeyer I. Treating depression in pregnancy: Practical suggestions. Cleve Clin J Med 73 (2006) 1098-1104
38. Raudzus J., and Misri S. Managing unipolar depression in pregnancy. Curr Opin Psychiatry 22 (2008) 13-18
39. Rahimi R., Nikfar S., and Abdollah M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: A meta-analysis of clinical trials. Reprod Toxicol 22 (2006) 571-575
40. Hemels M.E., Einarson A., Koren G., Lanctôt K.L., and Einarson T.R. Antidepressant use during pregnancy and the rates of spontaneous abortions: A meta-analysis. Ann Pharmacother 39 (2005) 803-809
41. GlaxoSmithKline Web site. US: December 2005 communication and recommendations to health care professionals. Available from: http://us.gsk.com/docs-pdf/media-news/pregnancy_hcp_letter.pdf [Accessed July 11 2009].
42. Bar-Oz B., Einarson T., Einarson A., Boskovic R., O'Brien L., Maim H., et al. Paroxetine and congenital malformations: Meta-analysis and consideration of potential confounding factors. Clin Ther 29 (2007) 918-926
43. US Food and Drug Adminstration Web site. FDA advising of risk of birth defects with Paxil. Agency requiring updated product labeling. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108527.htm [Accessed July 11, 2009].
44. Louik C., Lin A., Werler M.M., Hernancez-Diaz S., and Mitchell A.A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356 (2007) 2675-2683
45. Diav-Citrin O., Shechtman S., Weinbaum W., Wajnberg R., Avgil M., Di Gianantonio E., et al. Paroxetine and fluoxetine in pregnancy: A prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 66 (2008) 695-705
46. Alwan S., Reefhuis J., Rasmussen S.A., Olney R.S., and Friedman J.M. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356 (2007) 2684-2692
47. Einarson A., Pistelli A., DeSantis M., Malm H., Paulus W.D., Panchaud A., et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 165 (2008) 749-752
48. Källén B., and Olausson P.O. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 17 (2008) 801-806
49. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., Werler M.M., Louik C., Jones K.L., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354 (2006) 579-587
50. Andrade S.E., McPhillips H., Loren D., Raebel M.A., Lane K., Livingston J., et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 18 (2009) 246-252
51. Way C. Safety of newer antidepressants in pregnancy. Pharmacotherapy 27 (2007) 546-552
52. Casper R.C., Fleisher B.E., Lee-Ancajas J.C., Gilles A., Gaylor E., DeBattista A., et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 142 (2003) 402-408
53. Oberlander T.F., Grunau R., Mayes M., Riggs W., Rurak D., Papsdorf M., et al. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev 84 (2008) 689-697
54. Buitelaar J.K., Huizink A.C., Mulder E.J., de Medina P.G., and Visser G.H. Prenatal stress and cognitive development and temperament in infants. Neurobiol Aging 24 suppl 1 (2003) S53-S60
55. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 28 (2005) 137-152
56. Misri S., and Kendrick K. Treatment of perinatal mood and anxiety disorders: A review. Can J Psychiatry 52 (2007) 489-498
57. Hendrick V., Stowe Z.N., Altshuler L.L., Hwang S., Lee E., and Haynes D. Placental passage of antidepressant medications. Am J Psychiatry 160 (2003) 993-996
58. Cohen L.S., Altshuler L.L., Harlow B.L., Nonacs R., Newport D.J., Viguera A.C., et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295 (2006) 499-507
59. Cohen L.S., Altshuler L.L., Stowe Z.N., and Faraone S.V. Reintroduction of antidepressant therapy across pregnancy in women who previously discontinued treatment. A preliminary retrospective study. Psychother Psychosom 73 (2004) 255-258
60. Einarson T.R., and Einarson A. Newer antidepressants in pregnancy and rates of major malformations: A meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 14 (2005) 823-827
61. Leykin Y., Amsterdam J., DeRubeis R., Gallop R., Shelton R., and Hollon S. Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J Consult Clin Psych 75 (2007) 267-276
62. Gregoire A.J., Kumar R., Everitt B., Henderson A.F., and Studd J.W. Transdermal estrogen for the treatment of severe post-natal depression. Lancet 347 (1996) 930-933
63. Eberhard-Gran M., Eskild A., and Opjordsmoen S. Use of psychotropic medications in treating mood disorders during lactation: Practical recommendations. CNS Drugs 20 (2006) 187-198
64. Van den Bergh B., Van Calster B., Smits T., Van Huffel S., and Lagae L. Antenatal maternal anxiety is related to HPA-axis dysregulation and self-reported depressive symptoms in adolescence: A prospective study on the fetal origins of depressed mood. Neuropsychopharmacology 33 (2008) 536-545
65. Einarson A., Schachtschneider A.K., Halil R., Bollano E., and Koren G. SSRI'S and other antidepressant use during pregnancy and potential neonatal adverse effects: Impact of a public health advisory and subsequent reports in the news media. BMC Pregnancy Childbirth 5 (2005) 11
66. Office of Women's Health Web site. Achieving remission in depression: Managing women and men in the primary care setting. Available from: www.4women.gov/healthpro/edu/clinical_Courier_8.pdf [Accessed November 24, 2009].
67. Weissman M.M., Pilowsky D.J., Wickramaratne P.J., Talati A., Wisniewski S.R., Fava M., et al. Remissions in maternal depression and child psychopathology: A STAR*D-Child Report. JAMA 295 (2006) 1389-1398
68. Gentile S., and Bellantuono C. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: Focus on paroxetine. J Clin Psychiatry 70 (2009) 414-422
69. Sivojelezova A., Shuhaiber S., Sarkissian L., Einarson A., and Koren G. Citalopram use in pregnancy: Prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 193 (2005) 2004-2009
70. Chun-Fai-Chan B., Koren G., Fayez I., Kalra S., Voyer-Lavigne S., Boshier A., et al. Pregnancy outcome of women exposed to bupropion during pregnancy: A prospective comparative study. Am J Obstet Gynecol 192 (2005) 932-936